ClinicalTrials.gg
RecruitingNCT06287970Updated Nov 28, 2025

TaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPS

An interventional study of Transcutaneous Auricular Vagus Nerve Stimulation and Sham Transcutaneous Auricular Vagus Nerve Stimulation in Chronic Prostatitis, sponsored by Jiani Wu. Recruiting at 1 site in China. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Jiani Wu · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Prostatitis with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Prostatitis · China.

Planned enrollment
8th of 12
68 · median 211
Started
2024
the only one that year
No phase
8 of 13
1 open now
Registered
12th of 13
by date
Lead sponsor
1 of 13
Jiani Wu

Among the 13 studies in Prostatitis with a site in China, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 8 with no phase, and was the 12th registered.

Prostatitis

89 studies on the registry are indexed under Prostatitis; 12 are open to participants now.

Browse Prostatitis studies →

Open to participants now

2 of the 13 studies in Prostatitis with a site in China are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 6 Prostatitis studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 50 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Prostatitis with a site in China, or all of them as a file.
02

Study summary

This trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) for moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). This study is a prospective, randomized, controlled trial. A total of 68 patients with CP/CPPS will be recruited. After baseline assessment, the patients will be randomized into taVNS group (n = 34) and sham-taVNS group (n = 34). The intervention of two group will last for 4 weeks with a 8-week follow-up period after the treatment. The National Institutes of Health chronic Prostatitis Symptom Score index (NIH-CPSI), International Prostate Symptom Score Scale (IPSS), European quality of Life-5 Dimensions Questionnaire (EQ-5D), self-rating anxiety Scale (SAS) and self-rating depression scale (SDS) will be assessed. The adverse events during the whole study will be recorded detailedly.

03

Conditions studied

  • Chronic Prostatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consistent with the diagnostic criteria of CP/CPPS of EAU or CAU, the clinical manifestations were recurrent and persistent prostate pain accompanied by abnormal urination and psychiatric symptoms, without infection or other obvious pathological conditions. The pain symptoms were mainly manifested as pain in the surrounding tissues centered on the prostate, and pain, swelling or discomfort in the scrotum, testis, lower abdomen, perineum, lumbosacral area, and medial thigh. Abnormal urination was characterized by frequent urination, urgent urination, urination pain, urethral burning, residual urination or white discharge from the urethra at the end of urination or defecation in the morning. The neuropsychiatric symptoms included dizziness and tinnitus, insomnia and dreams, anxiety and depression, and even impotence, premature ejaculation, and spermatorrhea. Symptoms lasting more than 3 months in the last six months
  • 18 ≤ Age ≤ 50 years old
  • NIH-CPSI ≥15 (patients with moderate to severe CP/CPPS)
  • Signed and voluntarily participated in the trial

Exclusion criteria

Exclusion Criteria:

  • Patients with other diseases that cause urinary symptoms were excluded: Such as benign prostatic hyperplasia, testicular and epididymal and spermatic cord diseases, overactive bladder, neurogenic bladder, interstitial cystitis, glandular cystitis, sexually transmitted diseases, bladder tumors such as carcinoma in situ, prostate cancer, urinary male reproductive system tuberculosis, anorectal diseases, lumbar diseases, central and peripheral neuropathy, etc
  • Patients with severe diseases of the heart, liver, kidney, hematopoietic system and poor nutritional status
  • Patients with severe mental and emotional disorders, who were unable to cooperate with the study
  • Patients who have been treated with CP/CPPS regimen in the past 4 weeks
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    taVNS Group

    Bilateral auricular points of Xin (CO15) and Shen (CO10) will be stimulated by electrical stimulation. A disperse-dense wave will be used with a frequency of 4Hz/20Hz, a pulse width of 0.2ms will be set, and the current intensity will be modulated by the tolerance of the patient. note: taVNS, transcutaneous auricular vagus nerve stimulation

    Device: Transcutaneous Auricular Vagus Nerve Stimulation

  • Sham comparator
    Sham-taVNS Group

    Bilateral ear lobes will be stimulated by electrical stimulation. A disperse-dense wave will be used with a frequency of 4Hz/20Hz, a pulse width of 0.2ms and a current intensity of 0.1mA will be set. note: taVNS, transcutaneous auricular vagus nerve stimulation

    Device: Sham Transcutaneous Auricular Vagus Nerve Stimulation

Interventions

  • DeviceTranscutaneous Auricular Vagus Nerve Stimulation

    In the experimental group, bilateral auricular point Xin (CO15) and auricular point Shen (CO10) will be stimulated, on where the vagus nerves distributed.

  • DeviceSham Transcutaneous Auricular Vagus Nerve Stimulation

    In the control group, bilateral earlobes will be stimulated with no vagus nerve distribution.

06

What researchers measure

Primary outcomes

  1. Change from baseline in National Institute of Health Chronic Prostatitis Symptom Index(NIH-CPSI) total score at week 4

    The NIH-CPSI scale scores range from 0 to 43, with higher scores indicating more severe symptoms. The NIH-CPSI total score will be recorded once a week during the treatment period.

    Time frame: Baseline, week 4

Secondary outcomes

  1. Change from baseline in National Institute of Health Chronic Prostatitis Symptom Index(NIH-CPSI) total score at week 8 and week 12

    The NIH-CPSI scale scores range from 0 to 43, with higher scores indicating more severe symptoms. The NIH-CPSI total score will be recorded once a week during the treatment and follow-up period

    Time frame: Baseline, week 8 and 12

  2. The changes from baseline of NIH-CPSI pain score, urinary score and quality of life score, respectively at week 4, 8 and 12

    The NIH-CPSI scores range from 0 to 43. The NIH-CPSI has three subscores: pain scores , urinary scores , and quality of life scores. The subscore of pain ranged from 0 to 21. The subscores of urination symptoms ranged from 0 to 10. The subscore of the effect of symptoms on quality of life ranges from 0 to 12. The higher the score, the more severe the symptoms. These subitem scores are specific to the symptoms of CP/CPPS and do not require other separate outcome measures. Each part of the NIH-CPSI score will be recorded weekly during the treatment and follow-up periods

    Time frame: Baseline, week 4, 8 and 12

  3. Proportion of responders at week 4, 8 and 12

    Responder is defined as the patient with a decrease of ≥6 points in the NIH-CPSI total score compared with baseline. The proportion of responders will be calculated for each evaluation time point.

    Time frame: Baseline, week 4, 8 and 12

  4. The change from baseline in International Prostate Symptom Score (IPSS) score at week 4, 8 and 12

    The IPSS scale scores range from 0 to 35, with higher scores indicating more severe symptoms. The total IPSS score will be recorded once a week during the treatment and follow-up period

    Time frame: Baseline, week 4, 8 and 12

  5. The change from baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) at week 4, 8 and 12

    The EQ-5D is mainly composed of two parts, the Descriptive System and the Visual Analogue Scale (VAS) . The description system of EQ-5D can generate a five-digit health status, which can be intuitively reflected in the five health dimensions. This health status can be converted into a single summary number (utility index value) according to the characteristics of the general population in a country/region, which can be used to reflect the health status. The Visual Analogue Scale (VAS) contains a vertical scale ranging from 0 to 100 to record the self-rated health status of the participants. The Visual Analogue Scale provides a quantitative description of respondents' perceptions of their overall health. The EQ-5D total score will be recorded once a week during the treatment and follow-up period

    Time frame: Baseline, week 4, 8 and 12

  6. The change from baseline in Self-rating Anxiety Scale (SAS) at week 4, 8 and 12

    The standard score of the test result is obtained by summing the scores of the 20 items in the SAS scale, multiplying the resulting result by 1.25 and rounding to integer numbers. The cut-off value of the standard score is 53 points, with 53 to 62 points as mild depression, 63 to 72 points as moderate depression, and more than 73 points as severe depression. The total score of SAS will be recorded once a week during the treatment and follow-up period

    Time frame: Baseline, week 4, 8 and 12

  7. The change from baseline in the Self-rating Depression Scale (SDS) at week 4, 8 and 12

    The standard score of the test result is obtained by summing the scores of the 20 items in the SDS scale, multiplying the resulting result by 1.25 and rounding to integer numbers. The cut-off value of the standard score is 53 points, with 53 to 62 points as mild depression, 63 to 72 points as moderate depression, and more than 73 points as severe depression. The total score of SDS will be recorded once a week during the treatment and follow-up period

    Time frame: Baseline, week 4, 8 and 12

Other outcomes

  1. Evaluation of patient expectations

    Patients will be asked before the randomization: ① Do you think transcutaneous vagal nerve stimulation will be effective? ② Do you think transcutaneous vagal nerve stimulation will help improve your symptoms of chronic prostatitis/chronic pelvic floor pain syndrome?

    Time frame: Baseline before the randomization

  2. Blinding Evaluation

    Let the patient choose whether or not he or she has received the taVNS treatment after the treatment

    Time frame: at the end of week 4

  3. Incidence of Treatment-Emergent Adverse Events

    Treatment-related adverse events will be recorded and evaluated between two groups

    Time frame: The 4-week treatment period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wei X, Cui J, Zang Z, Pang R, Qi L, Wang Y, Wang HB, Wu Y, Qin Z, Wu J. Transcutaneous auricular vagus nerve stimulation for moderate to severe chronic prostatitis/chronic pelvic pain syndrome (TASC-P) in China: study protocol for a randomised controlled trial. BMJ Open. 2026 Jun 9;16(6):e106160. doi: 10.1136/bmjopen-2025-106160. PubMed 42264522 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in this article and any future publications from this study will be shared. This includes, but is not limited to: demographic information, clinical assessments, scores from the National Institutes of Health Chronic Prostatitis Symptom Score Index (NIH-CPSI), the International Prostate Symptom Score Scale (IPSS), the European Quality of Life Five-Dimensions Questionnaire (EQ-5D-5L), the Self-rating Anxiety Scale (SAS), and the Self-rating Depression Scale (SDS).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be available starting 6 months after publication of the primary results and will remain accessible for at least 5 years.

Access criteria: De-identified data will be made available to qualified researchers upon reasonable request. Researchers must submit a methodologically sound research proposal to the corresponding author at jiani_wu@aliyun.com. Access to the data will be granted after the requester signs a formal data access agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 21 interventional studies with no phase under Prostatitis, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's planned 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2024
First posted
Mar 1, 2024
StartActual
Mar 15, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 18, 2027
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06287970
Lead sponsor
Jiani Wu
Responsible party
Jiani Wu (Principal Investigator, Guang'anmen Hospital of China Academy of Chinese Medical Sciences) — Sponsor-investigator
First posted
Mar 1, 2024
Start date
Mar 15, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 18, 2027 (estimated)
Last update
Nov 28, 2025

Study contacts

Jiani Wu
Contact
jiani_wu@aliyun.com
+8613426116653

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion